SLC5A2 and type 2 diabetes mellitus: GLP-1 RAs are often grouped with SGLT-2 inhibitors, which prevent glucose reuptake in the kidney, as novel therapeutic approaches for the treatment of cardiovascular and renal disease in T2DM, but more research is needed for systematic differences in benefits and harms between them [19].